Expand GILD Menu
GILD MENU

GILD Latest Press Releases

-- April 8, 2024 --

Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024 Business Wire 4:05 PM

-- March 28, 2024 --

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six Business Wire 8:30 AM
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program Business Wire 7:00 AM
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program Globe Newswire 7:00 AM

-- March 22, 2024 --

Gilead Sciences Announces Completion of Acquisition of CymaBay Business Wire 9:18 AM

-- March 18, 2024 --

Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant Business Wire 7:29 PM

-- March 11, 2024 --

Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer Business Wire 8:24 AM

-- March 6, 2024 --

Biktarvy Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities Business Wire 4:30 PM
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 Business Wire 10:25 AM
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers Business Wire 8:00 AM

-- March 5, 2024 --

New Real-World Data Further Support the Use of Veklury (Remdesivir) for People Hospitalized With COVID-19 Business Wire 4:35 PM
Gilead's Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health Business Wire 4:30 PM
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs PRNewswire 7:00 AM

-- February 27, 2024 --

Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S. Business Wire 10:00 AM

-- February 26, 2024 --

U.S. FDA Approves Expanded Indication for Gilead's Biktarvy to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance Business Wire 4:05 PM
Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024 Business Wire 8:30 AM

-- February 20, 2024 --

Gilead Sciences to Present at Upcoming Investor Conferences Business Wire 4:05 PM
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication PRNewswire 7:00 AM

-- February 16, 2024 --

CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY Business Wire 1:58 PM

-- February 12, 2024 --

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics Business Wire 8:30 AM

-- February 9, 2024 --

Gilead Named One of America's Most JUST Companies by JUST Capital and CNBC Business Wire 11:00 AM

-- February 6, 2024 --

Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend Business Wire 4:05 PM
Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results Business Wire 4:02 PM

-- February 1, 2024 --

Ted Love, MD, Joins Gilead Sciences' Board of Directors Business Wire 4:31 PM

-- January 30, 2024 --

Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta CAR T-cell Therapy Business Wire 8:30 AM

-- January 29, 2024 --

Gilead and Arcus Announce Amended Collaboration and Equity Investment Business Wire 5:00 PM

-- January 23, 2024 --

Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024 Business Wire 4:05 PM

-- January 22, 2024 --

Gilead Provides Update on Phase 3 EVOKE-01 Study Business Wire 8:30 AM

-- December 21, 2023 --

Gilead Sciences to Present at Upcoming Investor Conference Business Wire 4:05 PM
U.S. FDA Approves Label Update for Kite's Yescarta CAR T-Cell Therapy to Include Overall Survival Data Business Wire 4:05 PM

-- December 20, 2023 --

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola PRNewswire 8:45 AM

-- December 19, 2023 --

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program Business Wire 7:00 AM

-- December 11, 2023 --

Analyses of Kite's Yescarta CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas Business Wire 9:00 PM
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite's Tecartus in Patients With Aggressive Blood Cancers Business Wire 7:30 PM
Long-Term Data for Kite's Yescarta CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma Business Wire 5:45 PM
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year Business Wire 12:00 PM

-- November 30, 2023 --

Gilead's Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023 Business Wire 8:30 AM